93 results
8-K
BTTX
Better Therapeutics Inc
11 Mar 24
Regulation FD Disclosure
9:01am
by these forward-looking statements including: risks related to commercial distribution, market acceptance and insurance reimbursement of AspyreRx
8-K
BTTX
Better Therapeutics Inc
4 Mar 24
Regulation FD Disclosure
8:51am
acceptance and insurance reimbursement of AspyreRx; Better Therapeutics’ ability to raise capital in the near term to fund its operations and continue
424B3
BTTX
Better Therapeutics Inc
28 Dec 23
Prospectus supplement
9:23pm
requirements;
developments and expectations relating to our competitors and our industry, including any regulatory developments;
the pricing, reimbursement … health outcomes and reduce costs to insurers.
We have conducted primary market research into the potential for reimbursement coverage of AspyreRx
8-K
08fjeschwx b5
13 Dec 23
Entry into a Material Definitive Agreement
5:06pm
8-K
EX-10.1
ntyhza4 ziwb
13 Dec 23
Entry into a Material Definitive Agreement
5:06pm
424B5
h39n8
9 Aug 23
Prospectus supplement for primary offering
4:37pm
424B5
e64liejyf74hlpa1nuv2
26 Jul 23
Prospectus supplement for primary offering
5:04pm
424B5
vlefz5a
11 May 23
Prospectus supplement for primary offering
5:20pm